GROW (Glioma Specialists Reaching Out With Support) Support

Dana-Farber Cancer Institute

Overview

This research study is being done to test a participant and caregiver-driven model of follow-up survivorship care,GROW Support (Glioma Specialists Reaching Out With Support), for post-treatment, low grade glioma patients.

This research study is a Feasibility Study, which examines if a supportive intervention for people with low grade gliomas (LGGs) and their caregivers is acceptable and feasible to patients and their caregivers. The research study procedures include: screening for eligibility and study interventions including filling out questionnaires and virtual or in-clinic supportive follow up visits to identify additional supportive needs that may arise. Participants will be in this research study for up to 6 months. It is expected that about 40 people will take part in this research study. The Levitan-Zabin Fund for GROW Support is supporting this research study by providing funds for research team members to do this study.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Conditions

Low-grade Glioma Survivorship Care Giving Burden

Interventions

GROW (Glioma Specialists Reaching Out With Support) Support ProgramBEHAVIORAL

Follow-up survivorship care plan for patients and caregivers

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient inclusion criteria include: * Must be at least 18 years of age; * Diagnosed with low grade glioma (WHO grade 1 or 2) * Completed active treatment within the last 2 years and are undergoing surveillance follow-up * Must have at least one caregiver willing to participate as indicated below * Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and are able to understand and willing to sign an electronic informed consent document. * Confirms willingness to undergo initial and follow-up questionnaire battery. * Caregiver inclusion criteria include: * Must be at least 18 years of age * Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and able to understand and willing to sign an electronic informed consent document * Consider themselves personally involved in the patient's care and decisions about the care they receive. Exclusion Criteria: * Bipolar disorder, * Psychotic disorders and * Confusion or altered mental state that would prohibit understanding and giving of informed consent. However, if the patient's bipolar disorder or psychotic disorder is currently treated/managed, the patient will be eligible for the study.

Locations (1)

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Retention Rate

Primary outcome is feasibility as defined by 60% of the eligible participants and their caregivers being recruited into the study and completing the initial assessment and associated survivorship plan

Time frame: 6 months

Secondary Outcomes

Abbreviated Acceptability Rating Profile

Acceptability of this supportive program ("GROW Support") for patients and their caregivers will be assessed by the Abbreviated Acceptability Rating Profile and based on in-depth semi-structured interview with one of the study investigators.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.